My question is....assuming we get + results, is when is the company going to finally cash up?  

Resverlogix has been running on fumes for so long....there are planned trials for CKD and Fabry's, and if the MOCA scores are good that'll mean trials for cognition...then there's the upcoming PAH trial, funded at leasat partially by Laval.....lots and lots of money needed, payroll costs alone I'm guessing have to be somewhere around $4 million p/yr alone.

Amarin cashed up big after their Reduce-It trial...to the tune of $200 million or so in November 2018.  I wonder how much Resverlogix would look to raise with successful BETonMACE results across all indications.